Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (90,195)	$ (37,138)
Loss from continuing operations	(90,195)	(31,139)
Loss from discontinued operations		(5,999)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	258	109
Stock-based compensation expenses	10,698	739
Loss on early extinguishment of debt	554
Change in fair value of preferred stock purchase right liability	980
Change in fair value of preferred stock warrant liability	105
Common stock issued in exchange for services	725	113
Noncash interest expense	553	1,589
Other		(15)
Changes in operating assets and liabilities:
Accounts receivable	7	(1,086)
Prepaid expenses and other current assets	(4,881)	(1,802)
Other assets	(971)
Accounts payable	103	(480)
Accrued compensation	2,655	1,738
Accrued expenses and other current liabilities	3,443	1,108
Payments made to PLI		(6,866)
Payable to PLI	(937)	1,130
Deferred revenue	13,398	4,931
Net cash used in operating activities – continuing operations	(63,505)	(29,931)
Net cash used in operating activities – discontinued operations		1,913
Net cash used in operating activities	(63,505)	(28,018)
Cash flows from investing activities
Purchase of property and equipment	(1,136)	(204)
Net cash used in investing activities – continuing operations	(1,136)	(204)
Net cash used in investing activities – discontinued operations		(859)
Net cash used in investing activities	(1,136)	(1,063)
Cash flows from financing activities
Proceeds from issuance of convertible preferred stock, net of issuance costs	73,749	73,826
Proceeds from issuance of long-term debt, net of issuance costs		7,338
Payments of stock issuance costs		(23)
Repayment of debt	(7,963)
Proceeds from sale of common stock in initial public offering	218,500
Payment of financing costs	(17,257)	(1,452)
Proceeds from issuance of common stock under employee stock purchase plan	428
Proceeds from issuance of common stock upon stock option exercises	237	197
Net cash provided by financing activities	267,694	79,886
Net increase in cash and cash equivalents	203,053	50,805
Cash and cash equivalents at beginning of period – continuing operations	54,201	4,450
Cash and cash equivalents at beginning of period – discontinued operations	4,975	3,921
Cash and cash equivalents cash at end of period	257,254	59,176
Cash and cash equivalents at end of period – discontinued operations		4,975
Cash and cash equivalents at end of period – continuing operations	257,254	54,201
Supplemental disclosures
Cash paid for income taxes	15	7
Cash paid for interest expense on Oxford debt	315	571
Supplemental schedule of non-cash investing and financing activities
Conversion of convertible preferred stock into common stock upon completion of initial public offering	210,810
Reclassification of preferred stock purchase right liability to equity due to issuance of Series D convertible preferred stock	4,880
Reclassification of warrant liability to equity due to conversion from preferred stock warrant to common stock warrant upon completion of initial public offering	169
Issuance of Series D-2 convertible preferred stock for the settlement of deferred purchase price	6,144
Acquisition-related consideration held in escrow		(3,500)
Issuance of Series C convertible preferred stock for deferred purchase price		5,000
Vesting of unvested issued common stock	32	38
Costs incurred, but not paid, in connection with capital expenditures included in accounts payable	153	181
Preferred stock purchase right liability	$ (4,880)	$ 3,900